SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Intellia Therapeutics, Inc. (NTLA) News

Follow Intellia Therapeutics, Inc. (NTLA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 30 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol NTLA Asset equity Sector Markets 90 days 26 Last 10.06 Updated Nov 05, 2026, 03:35 PM UTC Open live news feed Open NTLA chart & news
M Intellia Therapeutics Shares Fall 5% After Q3 Revenue Miss Intellia Therapeutics shares were down 5% in early trading after its Q3 revenue missed estimates. EQUITY | Nov 05, 2026, 03:35 PM UTC M Intellia Therapeutics Reports Quarterly Results The headline reports results for the quarter ended September 30; the body provides no financial figures. EQUITY | Nov 05, 2026, 03:25 PM UTC M Intellia Therapeutics Reports Q3 Revenue of $7.2 Million Q3 revenue was $7.2 million, versus a FactSet estimate of $9.7 million. EQUITY | Nov 05, 2026, 01:23 PM UTC M Intellia Therapeutics Reports Q3 Loss of $0.91 per Share The loss compares with a FactSet estimate of $0.80 per share. EQUITY | Nov 05, 2026, 01:14 PM UTC M Intellia Therapeutics Reports Third-Quarter Results and Business Updates The company said it remains on track with lonvo-z commercial readiness efforts ahead of a March 10, 2027 PDUFA date. EQUITY | Nov 05, 2026, 01:04 PM UTC L Intellia Therapeutics appoints Jing L. Marantz as chief medical officer EQUITY | Oct 13, 2026, 11:30 AM UTC H Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Thursday. Shares of Helen of Troy Limited (NASDAQ: HELE ) rose sharply after the company reported better-than-expected second-quarter adjuste LIVE | Oct 08, 2026, 01:53 PM UTC H Intellia Therapeutics Q2 2026 Earnings Call Transcript Intellia Therapeutics (NASDAQ: NTLA ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and LIVE | Oct 05, 2026, 10:28 AM UTC L Anthropic AI Discovery Gene-Editing Stocks Falling Gene-editing stocks fell Wednesday after Anthropic's Claude AI model identified an enzyme system with characteristics similar to technology used to alter DNA.Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia NEWS | Sep 24, 2026, 12:51 PM UTC L CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? Gene-editing stocks sold off on Wednesday after Anthropic said its Claude model had flagged a phage enzyme system that shares a few design traits with CRISPR — the platform behind approved and experimental DNA-editing me EQUITY | Sep 23, 2026, 09:49 PM UTC L Cathie Wood Makes Striking Switch Between AI Stock Giants Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms NASDAQ:META while selling a nearly identical dollar amount of Alphabet NAS EQUITY | Sep 15, 2026, 12:21 PM UTC L NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects The company is advancing in vivo gene editing with late-stage programs for HAE and TTR, expecting FDA approval for its HAE therapy by March 10. Strong efficacy and safety data support broad market potential, with a targe REGULATION | Sep 14, 2026, 10:01 PM UTC L NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and targeted launch plans The company is advancing late-stage in vivo gene editing therapies for HAE and TTR, with FDA review for HAE underway and a targeted commercial strategy in place. Strong clinical data, robust financial planning, and strat REGULATION | Sep 14, 2026, 09:13 PM UTC L Citizens maintains $30 price target on Intellia Therapeutics Citizens maintained its $30.00/share price target for Intellia Therapeutics. EQUITY | Sep 09, 2026, 01:14 PM UTC L Wedbush maintains Intellia Therapeutics at neutral Wedbush maintained its neutral rating on Intellia Therapeutics. EQUITY | Sep 09, 2026, 12:28 PM UTC L HC Wainwright maintains Intellia Therapeutics $25 price target HC Wainwright & Co. maintained its $25.00 per share price target for Intellia Therapeutics, according to Benzinga’s ratings actions. EQUITY | Sep 09, 2026, 10:44 AM UTC M Intellia says FDA accepted BLA for lonvo-z Intellia said the FDA accepted the BLA for lonvo-z, granted Priority Review and set a PDUFA action date of March 10, 2027. REGULATION | Sep 08, 2026, 08:15 PM UTC M FDA grants priority review for Intellia rare genetic disease therapy Intellia Therapeutics’ experimental gene-editing treatment for a rare genetic disease has received U.S. FDA priority review status, putting the stock back in focus among investors. REGULATION | Sep 08, 2026, 02:09 PM UTC M FDA accepts Intellia biologics license application for priority review Intellia Therapeutics said the U.S. FDA has accepted its biologics license application for lonvoguran ziclumeran (Lonvo-z) for hereditary angioedema (HAE) and granted priority review. REGULATION | Sep 08, 2026, 12:07 PM UTC M Intellia (NTLA) FDA accepts Lonvo-z BLA for hereditary angioedema Intellia Therapeutics said the FDA accepted its biologics license application for Lonvoguran ziclumeran (Lonvo-z) for hereditary angioedema and granted priority review. REGULATION | Sep 08, 2026, 12:00 PM UTC L Intellia awards inducement grants under Nasdaq Rule 5635(c)(4) Intellia Therapeutics said it awarded inducement grants on September 1, 2026 under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 04, 2026, 08:07 PM UTC L NTLA reports inducement grants under Nasdaq Rule 5635(c)(4) Intellia Therapeutics reported inducement grants under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 04, 2026, 08:05 PM UTC M Intellia Therapeutics lands non-dilutive OrbiMed debt facility up to $400M Intellia Therapeutics secured a non-dilutive debt facility with OrbiMed for up to $400 million: $75 million funded upfront and $325 million tied to milestones, aimed at added strategic flexibility. EQUITY | Sep 04, 2026, 12:57 PM UTC M NTLA secures non-dilutive debt facility with OrbiMed up to $400 million NTLA said it secured a non-dilutive debt facility with OrbiMed for up to $400 million. EQUITY | Sep 04, 2026, 12:50 PM UTC L Intellia Therapeutics to present at Morgan Stanley Global Healthcare conference Intellia Therapeutics said it will present at the Morgan Stanley 24th Annual Global Healthcare Conference. EQUITY | Sep 04, 2026, 12:07 PM UTC L NTLA - Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference NTLA - Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference EQUITY | Sep 04, 2026, 12:00 PM UTC L NTLA - Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates NTLA - Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates EARNINGS | Aug 06, 2026, 11:00 AM UTC L NTLA - Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates - Cli NTLA - Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates EARNINGS | Jul 30, 2026, 12:00 PM UTC L NTLA Downgrade from Peerperform to Underperform W/$9.00 PT at Wolfe Research NTLA Downgrade from Peerperform to Underperform W/$9.00 PT at Wolfe Research EQUITY | Jul 16, 2026, 11:54 AM UTC L NTLA downgraded from Peer Perform to Underperform W/ $9 PT @ Wolfe NTLA downgraded from Peer Perform to Underperform W/ $9 PT @ Wolfe EQUITY | Jul 16, 2026, 11:23 AM UTC